China Resources Sanjiu Investment Quality Review (000999.SZ)
Data timestamp: 2026-07-22 22:05 UTC
Quality score: 80/100
Valuation position: price/base fair value 0.65
Final signal: WATCHLIST
Core View
China Resources Sanjiu is rated WATCHLIST in this review. The report keeps the stock on the watchlist: business quality may be investable, but price and evidence do not yet support a buy signal. Current price is 25.16 CNY; conservative and base fair values are 22.38 CNY and 38.74 CNY per share. Price/base FV is 0.65, which is inside a potential buy-review zone, but still below the 2x standard unless independent valuation anchors agree.
The reviewed business exposure is OTC medicines, prescription drugs, health products and branded traditional medicine. The Chinese source anchors the conclusion in repeatable free cash flow, balance-sheet resilience, governance and capital-allocation evidence, then applies a valuation discount before deciding whether the stock deserves action. This English memo keeps the same signal, fair-value range, evidence limits, risk controls and review discipline.
Business Breakdown
The source report uses a five-year revenue and cash-flow view rather than a single-year extrapolation. The key economic question is whether the disclosed business mix can keep converting revenue into free cash flow through a normal cycle. Latest reported FCF in the financial table is 42.4 RMB 100m; that cash-flow anchor drives the valuation range more than headline revenue growth.
Segment profit, gross margin and management outlook are treated conservatively when disclosure is incomplete. A stronger product cycle, channel recovery, AI monetization, premiumization, or international growth can lift the watchlist only after it shows up in verified FCF, margin and per-share value evidence.
Business Quality Score
Quality is scored at 80/100. The scorecard covers business model quality, moat, repeatable cash flow, capital return, balance-sheet resilience, growth quality, and management/accounting. A high score does not by itself create a buy signal: the report still requires valuation support, a margin of safety and no unresolved material evidence gaps.
The main positive evidence is the existence of a five-year financial baseline with positive or analyzable cash-flow history and a balance sheet that can be bridged to common-equity value. The main constraints are the same as in the Chinese report: cyclical or regulatory exposure, disclosure depth, FCF durability, capital-allocation quality, incentive dilution, and whether current market expectations already price in too much improvement.
Financial Audit
The audit uses the complete fiscal years shown below, with the same quote currency, financial currency, FX treatment and risk-free-rate date as the Chinese source report. FCF is the primary valuation anchor; net profit, OCF, capex, FCF/Revenue and FCF/Net Income are used to check cash conversion rather than to create separate price targets.
| Year | Revenue | Net Profit | OCF | Capex | FCF | ROE | ROIC | FCF/Revenue | FCF/Net Income |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | 316.0 RMB 100m | 34.2 RMB 100m | 55.1 RMB 100m | 12.7 RMB 100m | 42.4 RMB 100m | 16.1% | 11.7% | 13.4% | 1.24 |
| 2024 | 276.2 RMB 100m | 33.7 RMB 100m | 44.0 RMB 100m | 7.9 RMB 100m | 36.1 RMB 100m | 17.3% | 14.0% | 13.1% | 1.07 |
| 2023 | 247.4 RMB 100m | 28.5 RMB 100m | 41.9 RMB 100m | 8.6 RMB 100m | 33.3 RMB 100m | 15.9% | 13.9% | 13.5% | 1.17 |
| 2022 | 180.8 RMB 100m | 24.5 RMB 100m | 30.1 RMB 100m | 9.5 RMB 100m | 20.5 RMB 100m | 15.2% | 14.4% | 11.4% | 0.84 |
| 2021 | 155.4 RMB 100m | 20.6 RMB 100m | 18.8 RMB 100m | 8.7 RMB 100m | 10.1 RMB 100m | 14.1% | 13.6% | 6.5% | 0.49 |
ROIC is not invented when the available structured fields cannot reliably reconstruct invested capital. When FCF/Net Income weakens or capex absorbs more operating cash, normalized FCF and the quality score must be revisited.
Balance Sheet Bridge
| Year | Cash | Current Financial Assets | Non-current Financial Assets | Total Debt | Net Cash / Net Debt |
|---|---|---|---|---|---|
| 2025 | 46.6 RMB 100m | 5.3 RMB 100m | 6.3 RMB 100m | 64.6 RMB 100m | -18.0 RMB 100m |
| 2024 | 50.2 RMB 100m | 5.0 RMB 100m | 3.2 RMB 100m | 13.2 RMB 100m | 37.0 RMB 100m |
| 2023 | 67.7 RMB 100m | 5.0 RMB 100m | 5.0 RMB 100m | 30.1 RMB 100m | 37.6 RMB 100m |
| 2022 | 31.5 RMB 100m | 2.7 RMB 100m | 2.4 RMB 100m | 4.0 RMB 100m | 27.5 RMB 100m |
| 2021 | 30.7 RMB 100m | 2.3 RMB 100m | 2.2 RMB 100m | 2.5 RMB 100m | 28.2 RMB 100m |
Cash, financial assets and debt are handled before common-equity fair value. Cash and liquid assets receive haircuts where composition or availability is uncertain; debt, leases, senior claims, dilution and contingent liabilities reduce value first.
Shareholder Returns
The Chinese report checks dividend yield, payout ratio, dividends/FCF, buybacks and dilution as capital-allocation evidence. These items are not double-counted as extra fair value. Dividends matter only when covered by repeatable FCF; buybacks matter only when they reduce share count at prices below intrinsic value; incentives matter when they improve or dilute ordinary shareholder economics.
This review does not upgrade the signal for a headline dividend or a recognizable brand. Shareholder return quality must reinforce the FCF valuation, not substitute for it.
Valuation
The valuation uses normalized FCF as the main anchor and adjusts for cash, financial assets, debt, dilution and other senior claims. Scenario outputs from the Chinese source are:
| Scenario | Fair Equity Value | Fair Value / Share | Price/FV | Weight | Required Follow-up |
|---|---|---|---|---|---|
| Conservative | 372.4 RMB 100m | 22.38CNY | 1.12 | 30% | FCF must not fall materially below the conservative anchor. |
| Base | 644.7 RMB 100m | 38.74CNY | 0.65 | 50% | Revenue, margin and capital-return evidence must remain intact. |
| Optimistic | 831.4 RMB 100m | 49.95CNY | 0.50 | 20% | Growth or quality rerating must be verified and cannot bypass the valuation cap. |
Base fair value is 38.74 CNY per share. The 2x discipline requires price/base FV at or below 0.50 and support from at least two independent valuation anchors. With price/base FV at 0.65, the report keeps valuation discipline ahead of narrative quality.
Buy And Tracking Discipline
Current action: WATCHLIST. A buy review requires price/base FV below 0.70, quality score no lower than 75, intact FCF conversion, no adverse balance-sheet shift, and stronger evidence that the market fear is temporary rather than structural. The 2x condition requires price/base FV below 0.50 plus a recheck of conservative FV.
Tracking priorities are revenue trend, FCF/Net Income, OCF/Net Income, ROIC or capital-return evidence, net cash or debt, financial-asset marks, dividend coverage, buyback price, incentive dilution, related-party risk and management outlook. If two reporting periods show weaker cash conversion, rising debt, financial-asset impairment, harmful dilution or worsening regulatory/competitive pressure, fair value and signal must be cut.
Risks To Recheck
Key risks are FCF durability, balance-sheet bridge reliability, shareholder-return quality, governance or accounting deterioration, and whether growth converts into per-share free cash flow. For high-multiple companies, even a good business can remain unattractive if current price already embeds optimistic growth and margin assumptions.
A downgrade is required if FCF/Net Income falls below the report threshold for two periods, debt or financial-asset impairments weaken downside protection, regulatory or competitive pressure worsens, or dividends, buybacks and incentives dilute ordinary shareholders instead of compounding value.
Sources
The evidence set follows the Chinese source report: market quote and share-count data, five-year financial baseline, official annual or interim filings, governance and incentive disclosures, dividends and buybacks, risk-free-rate references, and currency alignment. The Chinese source file is 2026-07-23/stock-audit-000999.SZ-2026-07-23.md, with source hash b8f76014026deb155c7911a6b8427420d23ec3dab4748c68c958bdc9eaa39bcf.
Research note: This memo is for personal research only and is not personalized investment advice.